Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Announces Departure of Chief Medical and Development Officer
Summary
Crinetics Pharmaceuticals, Inc. announced on December 16, 2025, that Dana Pizzuti, M.D., its Chief Medical and Development Officer, will step down effective December 31, 2025. Dr. Pizzuti will serve as a Strategic Regulatory and Development Advisor from January 1, 2026, through March 31, 2026, or until the Company terminates the agreement for Cause. During this transition period, she will receive a cash severance of $577,000 and will remain eligible for performance-based bonuses for 2025 and 2026. Additionally, she will continue to provide Advisory Services as an advisor starting April 1, 2026, through March 30, 2028, with compensation of $600 per hour and reimbursement for related expenses. The agreements include provisions for non-use and non-disclosure of confidential information, as well as the assignment of any inventions to the Company.
Profitelligence Alerts
Get alerts for CRNX
Be first to know when Crinetics Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.
Official SEC Documents
Advertisement